HCW Biologics gets Nasdaq extension to regain $1 minimum bid compliance by July 29
HCW Biologics
HCW Biologics HCWB | 0.00 |
- HCW Biologics received a Nasdaq notice for failing to maintain a $1 minimum bid price for 30 consecutive business days under Listing Rule 5550(a)(2).
- Nasdaq’s hearings panel granted an extension to regain compliance, requiring a bid price of at least $1 for 20 consecutive trading days by July 29, 2026.
- Any renewed bid-price deficiency before Sept. 22, 2026 triggers immediate delisting.
- Any other listing-rule breach before Sept. 22, 2026 requires a cure plan within seven days, subject to panel approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-026529), on June 01, 2026, and is solely responsible for the information contained therein.
